CNS Pharmaceuticals to Delist from Nasdaq, Move to OTCQB
Ticker: CNSP · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2.5 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, regulatory-compliance, stock-exchange
TL;DR
**CNS Pharmaceuticals is getting delisted from Nasdaq on Feb 23rd for not meeting the $1 bid price and will trade on OTCQB.**
AI Summary
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) received a delisting notice from Nasdaq on February 14, 2024, due to its failure to maintain the minimum bid price of $1.00 per share. The company's common stock will be suspended from trading on Nasdaq at the opening of business on February 23, 2024, and will begin trading on the OTCQB Venture Market under the symbol 'CNSP' on the same day. This move follows a previous notice from Nasdaq on August 17, 2023, regarding the same non-compliance.
Why It Matters
Delisting from Nasdaq can significantly reduce a company's visibility and liquidity, making it harder to raise capital and potentially impacting investor confidence and stock price.
Risk Assessment
Risk Level: high — Delisting from a major exchange like Nasdaq to the OTCQB Venture Market significantly increases investment risk due to reduced liquidity, less stringent reporting requirements, and lower investor confidence.
Key Numbers
- $1.00 — Minimum Bid Price (The threshold CNS Pharmaceuticals failed to maintain for Nasdaq listing.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — registrant facing delisting
- Nasdaq (company) — exchange delisting CNS Pharmaceuticals
- $1.00 (dollar_amount) — minimum bid price requirement
- February 14, 2024 (date) — date of delisting notice
- February 23, 2024 (date) — date of Nasdaq suspension and OTCQB trading commencement
- OTCQB Venture Market (company) — new trading venue for CNS Pharmaceuticals
- August 17, 2023 (date) — date of previous Nasdaq non-compliance notice
FAQ
What is the primary reason for CNS Pharmaceuticals, Inc.'s delisting from Nasdaq?
CNS Pharmaceuticals, Inc. is being delisted from Nasdaq because it failed to maintain the minimum bid price of $1.00 per share, as stated in the notice received on February 14, 2024.
When will CNS Pharmaceuticals' common stock be suspended from trading on Nasdaq?
The common stock of CNS Pharmaceuticals, Inc. will be suspended from trading on Nasdaq at the opening of business on February 23, 2024.
Where will CNS Pharmaceuticals' stock trade after delisting from Nasdaq?
After delisting from Nasdaq, CNS Pharmaceuticals' common stock will begin trading on the OTCQB Venture Market under the symbol 'CNSP' at the opening of business on February 23, 2024.
Has CNS Pharmaceuticals received a similar notice from Nasdaq before?
Yes, CNS Pharmaceuticals, Inc. previously received a notice from Nasdaq on August 17, 2023, regarding non-compliance with the minimum bid price requirement.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is February 14, 2024, which is the date CNS Pharmaceuticals, Inc. received the delisting notice from Nasdaq.
Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-02-21 17:00:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
- $2.5 million — that the Company maintain a minimum of $2.5 million in stockholders' equity, in the event t
Filing Documents
- cns_8k.htm (8-K) — 29KB
- 0001683168-24-001099.txt ( ) — 200KB
- cnsp-20240214.xsd (EX-101.SCH) — 3KB
- cnsp-20240214_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240214_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule. On August 17, 2023, CNS Pharmaceuticals, Inc. (the "Company") received a letter (the "Letter") from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which notified the Company that it does not presently comply with Nasdaq's Listing Rule 5550(b) (the "Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, in the event that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. Based on the Staff's review and the materials provided to the Staff by the Company, the Staff granted the Company's request for an extension until February 13, 2024, to comply with this requirement. On February 14, 2024, the Staff notified the Company that it had not complied with the Listing Rule and as such did not meet the terms of the extension. The Staff letter stated that unless the Company timely requests a hearing before a Hearings Panel (the "Panel"), the Company would be subject to delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, the Panel has the discretion to grant the Company an extension not to exceed August 12, 2024. Notwithstanding, there can be no assurance that the Panel will grant the Company a further extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly aut